FDA will consider making its process for determining generic drug exclusivity awards public, an idea that would increase agency transparency and also continue the formalization of the agency’s generic drug system.
During a public hearing that will be used to set fiscal year 2015 policy priorities for the generic drug user fee program, FDA wants comments on potential new processes under...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?